How AI is Fixing the Sleep Data Bottleneck in Global Clinical Trials

BOSTON, MA – October 01, 2026

In the high-stakes ecosystem of global drug development, the most profound bottlenecks often hide in plain sight. For decades, clinical trials measuring sleep—whether testing a novel insomnia therapeutic, evaluating a cardiovascular intervention, or validating a consumer wellness device—have relied on a distinctly analog process: human beings manually scoring polysomnography (PSG) data. It is a slow, expensive, and inherently subjective methodology that introduces a dangerous amount of noise into clinical data.

Today, that paradigm is shifting. HoneyNaps, a sleep health technology company best known for its artificial intelligence diagnostic software, announced a major strategic pivot. The company is officially expanding its SOMNUM platform beyond software licensing and into specialized clinical analysis services. By registering as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT), HoneyNaps is transitioning from a technology vendor into a full-stack clinical partner.

This maneuver is not merely a corporate restructuring. It represents a fundamental shift in how the pharmaceutical and medical device industries will capture, quantify, and validate physiological data in the years to come. By replacing human subjectivity with algorithmic precision, the industry is finally finding the signal in the noise of sleep research.

Tackling the Bottleneck: Standardizing Sleep Endpoints

To understand the significance of this expansion, one must first understand the structural flaw in traditional sleep data analysis. In a standard multicenter clinical trial, a patient's sleep architecture—comprising brain waves, blood oxygen levels, heart rate, and breathing—is recorded via polysomnography. This generates massive datasets that must be divided into 30-second intervals, or "epochs," and classified into specific sleep stages (Wake, N1, N2, N3, and REM).

Historically, this task has fallen to certified sleep technologists. However, human interpretation is fraught with inter-rater variability. Studies have consistently shown that even highly trained technicians at different institutions may only agree on 85 to 90 percent of epochs. In the context of a multi-million-dollar pharmaceutical trial, a 10 to 15 percent variance in primary endpoint data can be disastrous, potentially obscuring a drug's efficacy or masking subtle side effects. Furthermore, manual scoring is agonizingly slow. Industry analyses indicate that a human scorer requires an average of 4,243 seconds (over an hour) to score a single patient record.

HoneyNaps is deploying its SOMNUM platform to eliminate this friction. The AI-powered system, which recently secured U.S. Food and Drug Administration (FDA) 510(k) clearance (K253390) for its V3.0 iteration in July 2026, reduces that scoring time to a staggering 42.7 seconds.

More importantly, it solves the reproducibility crisis. Clinical validation studies involving 400 subjects demonstrated that SOMNUM's deep learning algorithms achieve remarkable parity with expert consensus, boasting agreement rates between 92 and 99 percent across various sleep stages. For critical respiratory events—such as detecting and classifying obstructive, central, and mixed sleep apnea—the system achieved an Overall Percent Agreement (OPA) of more than 97 percent. By routing multicenter trial data through a single, standardized algorithmic engine, pharmaceutical sponsors can effectively eliminate the institutional variability that has long plagued sleep research.

From Diagnostic Tool to CRO: A Strategic Expansion

The decision by HoneyNaps to evolve into a registered CRO is a calculated response to broader macroeconomic shifts in medical research. The market for artificial intelligence in clinical trials was valued at approximately $1.3 billion in 2023 and is projected to surge toward $22.89 billion by 2034. As trial complexity increases and R&D budgets face stricter scrutiny, pharmaceutical sponsors are aggressively seeking partners who can accelerate data analysis without compromising regulatory rigor.

While traditional CROs like CTI and Medpace have built formidable sleep research divisions relying on human expertise and operational scale, a new class of specialized, tech-first organizations is emerging. Competitors such as BioSerenity and AstraOne have also recognized the value of automated PSG scoring. However, HoneyNaps is differentiating itself by heavily leveraging its proprietary, FDA-cleared SOMNUM engine as the foundational infrastructure for its clinical services, having already supported trials involving over 10,000 participants.

This vertical integration allows the company to capture more value from the drug development pipeline. Instead of merely licensing software to third-party research organizations, HoneyNaps is now positioned to manage the data lifecycle directly.

"Pharmaceutical companies, device developers, and research organizations pursue different research objectives, but they share a need for objective and consistent sleep data," said Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA. "As more customers across these sectors turn to HoneyNaps to obtain such data, we are expanding both the applications of our existing scoring technology and the business areas that contribute to revenue. We will continue to support the generation of clinical evidence through endpoints suited to each study and standardized analysis criteria, while diversifying our revenue base."

Beyond Scoring: Polysomnography as the Next Frontier for Digital Biomarkers

While standardizing sleep stages and counting respiratory events are the immediate commercial drivers for HoneyNaps' CRO services, the long-term strategic play revolves around digital biomarkers. Sleep is increasingly recognized not just as a state of rest, but as a critical window into systemic health.

The granular physiological data captured during a night of sleep—subtle shifts in respiratory patterns, micro-arousals, and variations in oxygen saturation—contains predictive signals for a host of morbidities. The pharmaceutical industry is currently exploring how these metrics can serve as foundational evidence for future digital biomarkers in trials targeting cardiovascular disease, neurodegeneration, and metabolic disorders.

HoneyNaps is actively developing next-generation analytics to capture these complex signals. Metrics such as Hypoxic Burden (the cumulative depth and duration of oxygen desaturation during sleep), Arousal Burden, and Ventilatory Burden are moving beyond academic theory and into clinical application. By quantifying these burdens, researchers can more accurately evaluate a patient's risk profile and their physiological response to experimental therapies.

For a biotech company testing a novel heart failure medication, the ability to objectively measure a reduction in a patient's Hypoxic Burden during sleep could provide early, compelling evidence of drug efficacy long before traditional clinical endpoints are met. By positioning itself at the intersection of artificial intelligence, clinical trial operations, and digital biomarker development, HoneyNaps is doing more than just speeding up data analysis. It is actively redefining the infrastructure of medical innovation, ensuring that the subtle signals of human physiology are no longer lost in the noise of subjective interpretation.